S&P 500   4,273.53 (-1.47%)
DOW   33,618.88 (-1.14%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.41 (+0.72%)
BABA   85.91 (-1.50%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.43 (-1.19%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.20%)
GE   109.93 (-1.60%)
DIS   80.05 (-1.19%)
AMC   7.91 (-2.83%)
PFE   32.40 (-1.76%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
S&P 500   4,273.53 (-1.47%)
DOW   33,618.88 (-1.14%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.41 (+0.72%)
BABA   85.91 (-1.50%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.43 (-1.19%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.20%)
GE   109.93 (-1.60%)
DIS   80.05 (-1.19%)
AMC   7.91 (-2.83%)
PFE   32.40 (-1.76%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
S&P 500   4,273.53 (-1.47%)
DOW   33,618.88 (-1.14%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.41 (+0.72%)
BABA   85.91 (-1.50%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.43 (-1.19%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.20%)
GE   109.93 (-1.60%)
DIS   80.05 (-1.19%)
AMC   7.91 (-2.83%)
PFE   32.40 (-1.76%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
S&P 500   4,273.53 (-1.47%)
DOW   33,618.88 (-1.14%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.41 (+0.72%)
BABA   85.91 (-1.50%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.43 (-1.19%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.20%)
GE   109.93 (-1.60%)
DIS   80.05 (-1.19%)
AMC   7.91 (-2.83%)
PFE   32.40 (-1.76%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
NASDAQ:ADMP

Adamis Pharmaceuticals (ADMP) Stock Forecast, Price & News

$0.78
+0.01 (+0.86%)
(As of 09/7/2023)
Compare
Today's Range
$0.75
▼
$0.79
50-Day Range
$0.77
▼
$3.99
52-Week Range
$0.75
▼
$26.18
Volume
119,800 shs
Average Volume
811,695 shs
Market Capitalization
$7.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

ADMP stock logo

About Adamis Pharmaceuticals (NASDAQ:ADMP) Stock

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.

ADMP Price History

ADMP Stock News Headlines

September 26, 2023 | americanbankingnews.com
Adamis Pharmaceuticals (NASDAQ:ADMP) Earns Sell Rating from Analysts at StockNews.com
September 19, 2023 | americanbankingnews.com
StockNews.com Initiates Coverage on Adamis Pharmaceuticals (NASDAQ:ADMP)
September 26, 2023 | Micro-Cap Stock Trader (Ad)
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
September 7, 2023 | msn.com
Adamis changes name to DMK Pharmaceuticals, ticker to DMK
September 7, 2023 | finance.yahoo.com
Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus
August 21, 2023 | finanznachrichten.de
Adamis Pharmaceuticals Corporation: Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 21, 2023 | finance.yahoo.com
Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 4, 2023 | finance.yahoo.com
Adamis Pharmaceuticals Announces Closing of $8.0 Million Public Offering
September 26, 2023 | Micro-Cap Stock Trader (Ad)
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
August 2, 2023 | finance.yahoo.com
Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering
August 1, 2023 | msn.com
Adamis Pharmaceuticals Stock Soars To More Than Double - What's Going On?
August 1, 2023 | msn.com
Adamis stock soars as high as 480% amid asset sale, drug study news
July 28, 2023 | marketwatch.com
Adamis Pharma to Fund Clinical Study with University of Leiden Opioid Expert
July 28, 2023 | finance.yahoo.com
Adamis Pharmaceuticals to Fund ZIMHI® Clinical Study with University of Leiden Opioid Expert
June 26, 2023 | benzinga.com
Adamis Pharmaceuticals Announces NIH Grant Funding For Treatment Of Alcohol Use Disorder, Size Not Disclosed
June 26, 2023 | finance.yahoo.com
Adamis Pharmaceuticals Announces NIH Grant Funding for the Treatment of Alcohol Use Disorder
June 22, 2023 | finance.yahoo.com
Adamis Pharmaceuticals Participated in White House Meeting Regarding Opioid Overdose Prevention
June 4, 2023 | fool.com
Adamis Pharmaceuticals (NASDAQ: ADMP)
May 31, 2023 | benzinga.com
Adamis Pharmaceuticals CEO Awarded $210K Worth of Stock Options
May 31, 2023 | benzinga.com
Board Member at Adamis Pharmaceuticals Acquires Company Stock Options Worth 25,720 Shares
May 26, 2023 | finanznachrichten.de
Adamis Pharmaceuticals Corporation: Adamis Pharmaceuticals Announces Closing of the Merger with DMK Pharmaceuticals
May 25, 2023 | finance.yahoo.com
Adamis Pharmaceuticals Announces Closing of the Merger with DMK Pharmaceuticals
May 21, 2023 | seekingalpha.com
Adamis Pharma slips 19% on plans for reverse stock slip
May 19, 2023 | finanznachrichten.de
Adamis Pharmaceuticals Corporation: Adamis Pharmaceuticals Announces Reverse Stock Split
May 19, 2023 | finance.yahoo.com
Adamis Pharmaceuticals Announces Reverse Stock Split
May 16, 2023 | finance.yahoo.com
Q1 2023 Adamis Pharmaceuticals Corp Earnings Call
May 15, 2023 | finance.yahoo.com
Adamis Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
See More Headlines
Receive ADMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adamis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ADMP Company Calendar

Last Earnings
3/31/2022
Today
9/26/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ADMP
CUSIP
N/A
CIK
887247
Web
www.adamispharmaceuticals.com
Phone
(858) 997-2400
Fax
N/A
Employees
11
Year Founded
2006

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-26,480,000.00
Net Margins
-502.73%
Pretax Margin
-471.80%
Return on Equity
-420.53%
Return on Assets
-256.87%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.23
Quick Ratio
0.19

Sales & Book Value

Annual Sales
$4.76 million
Price / Sales
1.52
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($1.26) per share
Price / Book
-0.62

Miscellaneous

Outstanding Shares
9,360,000
Free Float
9,237,000
Market Cap
$7.25 million
Optionable
Optionable
Beta
1.27

Social Links

Beginners Guide To Retirement Stocks Cover
Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. David J. Marguglio (Age 53)
    Co-Founder, Interim CFO. Pres & COO
    Comp: $526.35k
  • Dr. Ebrahim Versi M.D. (Age 70)
    Ph.D., CEO & Chair of the Board
  • Ms. Jennifer C. Suski
    Sr. Director of Marketing
  • Mr. Eddie Wabern Glover (Age 73)
    Chief Exec. Officer of US Compounding Inc
  • Mr. Robert B. Rothermel (Age 79)
    Consultant

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













ADMP Stock - Frequently Asked Questions

How have ADMP shares performed in 2023?

Adamis Pharmaceuticals' stock was trading at $11.8510 on January 1st, 2023. Since then, ADMP shares have decreased by 93.5% and is now trading at $0.7751.
View the best growth stocks for 2023 here.

When is Adamis Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our ADMP earnings forecast.

How were Adamis Pharmaceuticals' earnings last quarter?

Adamis Pharmaceuticals Co. (NASDAQ:ADMP) announced its quarterly earnings results on Thursday, March, 31st. The specialty pharmaceutical company reported ($4.20) EPS for the quarter, missing the consensus estimate of ($2.80) by $1.40. Adamis Pharmaceuticals had a negative net margin of 502.73% and a negative trailing twelve-month return on equity of 420.53%. During the same quarter in the prior year, the company posted ($11.20) EPS.

When did Adamis Pharmaceuticals' stock split?

Adamis Pharmaceuticals's stock reverse split on Monday, May 22nd 2023. The 1-70 reverse split was announced on Monday, May 22nd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 22nd 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

What other stocks do shareholders of Adamis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adamis Pharmaceuticals investors own include Trevena (TRVN), Amarin (AMRN), Sorrento Therapeutics (SRNE), Verastem (VSTM), Dynavax Technologies (DVAX), Novavax (NVAX), SCYNEXIS (SCYX), Synergy Pharmaceuticals (SGYP), Agile Therapeutics (AGRX) and OPKO Health (OPK).

What is Adamis Pharmaceuticals' stock symbol?

Adamis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMP."

Who are Adamis Pharmaceuticals' major shareholders?

Adamis Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (1.42%), Geode Capital Management LLC (0.68%), Citadel Advisors LLC (0.00%) and Simplex Trading LLC (0.00%). Insiders that own company stock include David C Benedicto, David J Marguglio, Dennis J Phd Carlo, Robert O Hopkins and Ronald B Moss.
View institutional ownership trends.

How do I buy shares of Adamis Pharmaceuticals?

Shares of ADMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adamis Pharmaceuticals' stock price today?

One share of ADMP stock can currently be purchased for approximately $0.78.

How much money does Adamis Pharmaceuticals make?

Adamis Pharmaceuticals (NASDAQ:ADMP) has a market capitalization of $7.25 million and generates $4.76 million in revenue each year.

How can I contact Adamis Pharmaceuticals?

Adamis Pharmaceuticals' mailing address is 11682 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The official website for the company is www.adamispharmaceuticals.com. The specialty pharmaceutical company can be reached via phone at (858) 997-2400 or via email at mflather@adamispharma.com.

This page (NASDAQ:ADMP) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -